Tango Therapeutics (TNGX) R&D president exercises options and sells stock

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tango Therapeutics, Inc. President of R&D Crystal Adam exercised stock options to acquire 38,460 shares of common stock at an exercise price of $5.20 per share, then sold 38,460 shares in an open-market transaction at $25.00 per share. Following the sale, she directly holds 112,622 common shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.

Insider Trade Summary 10b5-1

Net Seller: 38,460 shares ($961,500)

Net Sell 3 txns

Insider Crystal Adam

Role President, R&D

Sold 38,460 shs ($962K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	38,460	$0.00	--
Exercise	Common Stock	38,460	$5.20	$200K
Sale	Common Stock	38,460	$25.00	$962K

Holdings After Transaction: Stock Option (Right to Buy) — 395,040 shares (Direct); Common Stock — 151,082 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 38,460 shares Exercise price: $5.20/share Shares sold: 38,460 shares +4 more

7 metrics

Options exercised 38,460 shares Stock options exercised into common stock on April 15, 2026

Exercise price $5.20/share Strike price for exercised stock options

Shares sold 38,460 shares Open-market sale of common stock on April 15, 2026

Sale price $25.00/share Per-share price for open-market sale

Post-transaction holdings 112,622 shares Direct common stock held after transactions

Option expiration March 1, 2033 Expiration date for the reported stock option grant

10b5-1 plan adoption date October 27, 2025 Date the trading plan governing these trades was adopted

Key Terms

Stock Option (Right to Buy), Rule 10b5-1 trading plan, open-market sale, Exercise or conversion of derivative security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Rule 10b5-1 trading plan financial

"These transactions were effected ... pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vesting financial

"This option shall vest and become exercisable over a four-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/16/2026 - 08:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last)

(First)

(Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/15/2026		M⁽¹⁾		38,460	A	$5.2	151,082	D
Common Stock	04/15/2026		S⁽¹⁾		38,460	D	$25	112,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.2	04/15/2026		M⁽¹⁾			38,460	⁽²⁾	03/01/2033	Common Stock	38,460	$0	395,040	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Tango Therapeutics (TNGX) report for Crystal Adam?

Tango Therapeutics reported that President of R&D Crystal Adam exercised options for 38,460 common shares at $5.20, then sold 38,460 shares at $25.00 in an open-market transaction, all on April 15, 2026 under a Rule 10b5-1 plan.

How many Tango Therapeutics (TNGX) shares does Crystal Adam hold after this Form 4?

After the reported transactions, Crystal Adam directly holds 112,622 shares of Tango Therapeutics common stock. This reflects her position following the same-day option exercise of 38,460 shares and the open-market sale of 38,460 shares disclosed in the Form 4.

At what prices did Crystal Adam exercise and sell Tango Therapeutics (TNGX) shares?

Crystal Adam exercised stock options at an exercise price of $5.20 per share and sold 38,460 Tango Therapeutics common shares at $25.00 per share. Both transactions occurred on April 15, 2026 and were executed under a Rule 10b5-1 trading plan.

Was the Tango Therapeutics (TNGX) insider sale by Crystal Adam pre-planned?

Yes. The Form 4 states that Crystal Adam’s transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were pre-arranged rather than discretionary trades timed on the transaction date.

What type of derivative security did Crystal Adam exercise at Tango Therapeutics (TNGX)?

Crystal Adam exercised a stock option, described as a “Stock Option (Right to Buy),” covering 38,460 underlying common shares at a $5.20 exercise price. The option was scheduled to vest over four years starting February 27, 2024, according to the vesting footnote.